Sangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated by Analysts at Wall Street Zen

Wall Street Zen assumed coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO - Free Report) in a report released on Thursday. The brokerage issued a hold rating on the biopharmaceutical company's stock.

SGMO has been the topic of several other reports. Truist Financial dropped their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Royal Bank of Canada restated a "sector perform" rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Finally, Barclays reduced their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $4.50.

Sangamo Therapeutics Trading Down 4.3%

SGMO stock traded down $0.02 during midday trading on Thursday, hitting $0.47. The company's stock had a trading volume of 2,505,854 shares, compared to its average volume of 8,743,457. The company has a market cap of $110.36 million, a PE ratio of -0.63 and a beta of 1.46. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The firm's 50-day moving average is $0.69 and its 200-day moving average is $1.27.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The business had revenue of $6.44 million during the quarter, compared to the consensus estimate of $7.90 million. Analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently made changes to their positions in the business. E Fund Management Co. Ltd. purchased a new position in shares of Sangamo Therapeutics during the fourth quarter valued at about $25,000. JPMorgan Chase & Co. boosted its position in shares of Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at approximately $28,000. Finally, Captrust Financial Advisors purchased a new stake in shares of Sangamo Therapeutics during the 4th quarter valued at about $30,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.